CAR T-cell Therapy for Myeloid Leukemia - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for CAR T-cell Therapy for Myeloid Leukemia including molecules at Phase I and Phase I/II stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, by territory, therapeutic modality, and target.

Overview of the drug development pipeline for CAR T-cell Therapy for Myeloid Leukemia  

Leukemia is the cancer of blood cells, that degenerates the death of damaged cells in comparison to normal cells. In patients suffering from leukemia, the damaged cells accumulate and reduce the space for normal cells to function and survive. Leukemia either develops or worsens quickly in acute leukemia or over a period of time in chronic leukemia. With extensive research in oncology, several therapeutics are being developed to treat and control the growth of the disease. In CAR-T cell therapy, the T-cells of the patients are genetically modified in the laboratory by adding chimeric antigen receptor to bind these cells. These receptors graft onto a monoclonal antibody onto a T-cell, that aids these cells in attacking the cancer cells. Technavio’s market research analysts identify CD19 to be the most common target for CAR T-cell therapy for myeloid leukemia (ML). This cell therapy is expressed on B-cells throughout their development and expressed nearly on all B-cell malignancies. The increasing number of pre-clinical studies identifies the effectiveness of CAR T-cell therapies against both forms of leukemia and its cancer cells.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the Phase I/II drug development stage, followed by significant share in Phase I drug development stage. The pipeline landscape in the pipeline analysis report also mentions the percentage of drug development molecules that are in the various stages. 

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of CAR T-cell Therapy for Myeloid Leukemia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

•  CARSGEN THERAPEUTICS
• HEBEI SENLANG BIOTECHNOLOGY
• JUNO THERAPEUTICS

Therapeutic assessment of the drug development pipeline for CAR T-cell Therapy for Myeloid Leukemia by route of administration

• Intravenous

The intravenous route of administration (ROA) involves the administration of drug substances directly into a vein. It has been observed that the majority of total therapeutics for CAR T-cell Therapy for Myeloid Leukemia are being developed for intravenous administration.  

Therapeutic assessment of the drug development pipeline for CAR T-cell Therapy for Myeloid Leukemia by therapies employed

• Monotherapy
• Monotherapy + combination therapy

According to this pipeline analysis report, majority of the molecules in the drug development pipeline for CAR T-cell Therapy for Myeloid Leukemia are employed as monotherapy. Monotherapy comprises of the use of a single drug to treat a particular disorder.  

Technavio also offers customization on reports based on specific client requirement.